Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Isabelle Mahé: Reduced-Dose Apixaban Lowers Bleeding Risk in CAT Without Losing Efficacy
Isabelle Mahé /LinkedIn
Mar 8, 2026, 07:17

Isabelle Mahé: Reduced-Dose Apixaban Lowers Bleeding Risk in CAT Without Losing Efficacy

Isabelle Mahé, Head of Internal Medicine at the Louis Mourier Hospital, APHP at Paris Cité University, shared a post on LinkedIn about several recent articles she and her colleagues co-authored, adding:

”In patients with CAT receiving extended treatment, reduced-dose apixaban is non inferior to full dose apixaban, and is associated with a significant 25% reduction in the risk of Clinically Relevant Bleeding․

4 clinical predictors were significantly associated with increased CRB risk:

  • anaemia and/or
  • thrombocytopenia,
  • age ≥75, PE as the index event,
  • male sex (The Lancet Haematology)․

The accumulation of bleeding risk predictors emerged as a major determinant of clinically relevant bleeding, with consistent patterns across dosing regimens. (The Lancet Haematology)․

In patients with bleeding risk predictors, a lower clinically relevant bleeding with reduced-dose apixaban was observed.

Those data reinforce the clinical relevance of the API-CAT findings, including for patients with non-modifiable bleeding risk factors․

Please read our reply just published in The Lancet Haematology!”

Title 1: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism

Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez

Read the Full Article on The New England Journal of Medicine․

Isabelle Mahé: Reduced-Dose Apixaban Lowers Bleeding Risk in CAT Without Losing Efficacy

Title 2: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial

Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti

Read the Full Article on The Lancet Haematology․

Isabelle Mahé: Reduced-Dose Apixaban Lowers Bleeding Risk in CAT Without Losing Efficacy

Title 3: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE – Authors’ reply

Authors: Isabelle Mahé, Céline Chapelle, Silvy Laporte

Read the Full Article on The Lancet Haematology․

Isabelle Mahé: Reduced-Dose Apixaban Lowers Bleeding Risk in CAT Without Losing Efficacy

Stay updated on all scientific advances with Hemostasis Today.

Apixaban Bleeding Risk Celine Chapelle Charles-Marc Samama Didier Mayeur Eric Vicaut Grigoris Gerotziafas Health Hélène Helfer Hematology Hemostasis Hemostasis News Hemostasis Today Isabelle Mahé Jean Chidiac Luis Jara-Palomares Marc Carrier Medicine Nicolas Falvo Olivier Sanchez Patrick Mismetti Philippe Girard Silvy Laporte The Lancet Haematology The New England Journal of Medicine
NewsFeed